This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Akero Therapeutics’s 8K filing here.
About Akero Therapeutics
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
- Five stocks we like better than Akero Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- What is a Low P/E Ratio and What Does it Tell Investors?
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- How to invest in marijuana stocks in 7 steps
- The Top 5 Performing S&P 500 Stocks YTD in 2024
